JP6798988B2 - 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたrasを抑制する方法及びその利用 - Google Patents
完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたrasを抑制する方法及びその利用 Download PDFInfo
- Publication number
- JP6798988B2 JP6798988B2 JP2017525496A JP2017525496A JP6798988B2 JP 6798988 B2 JP6798988 B2 JP 6798988B2 JP 2017525496 A JP2017525496 A JP 2017525496A JP 2017525496 A JP2017525496 A JP 2017525496A JP 6798988 B2 JP6798988 B2 JP 6798988B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- ras
- amino acid
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 80
- 230000001086 cytosolic effect Effects 0.000 title description 77
- 108060003951 Immunoglobulin Proteins 0.000 title description 41
- 102000018358 immunoglobulin Human genes 0.000 title description 41
- 230000008595 infiltration Effects 0.000 title description 33
- 238000001764 infiltration Methods 0.000 title description 33
- 210000004027 cell Anatomy 0.000 claims description 241
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 210000000805 cytoplasm Anatomy 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 19
- 210000001163 endosome Anatomy 0.000 claims description 17
- 239000002502 liposome Substances 0.000 claims description 16
- 239000012466 permeate Substances 0.000 claims description 15
- 229940126586 small molecule drug Drugs 0.000 claims description 15
- 230000012202 endocytosis Effects 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 230000000975 bioactive effect Effects 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 102000016914 ras Proteins Human genes 0.000 description 118
- 101150105104 Kras gene Proteins 0.000 description 90
- 230000027455 binding Effects 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 68
- 102200006539 rs121913529 Human genes 0.000 description 63
- 108010014186 ras Proteins Proteins 0.000 description 54
- 230000035772 mutation Effects 0.000 description 45
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 40
- 230000010261 cell growth Effects 0.000 description 38
- 102200006531 rs121913529 Human genes 0.000 description 36
- 150000001413 amino acids Chemical group 0.000 description 35
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 33
- 230000000149 penetrating effect Effects 0.000 description 32
- 239000002609 medium Substances 0.000 description 31
- 239000000126 substance Substances 0.000 description 29
- 239000013598 vector Substances 0.000 description 28
- 229910002091 carbon monoxide Inorganic materials 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 24
- 230000035515 penetration Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 230000003834 intracellular effect Effects 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 230000001976 improved effect Effects 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 230000003013 cytotoxicity Effects 0.000 description 17
- 231100000135 cytotoxicity Toxicity 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 101150117869 Hras gene Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 14
- 210000000170 cell membrane Anatomy 0.000 description 14
- 102200006532 rs112445441 Human genes 0.000 description 14
- 230000009870 specific binding Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 12
- 238000012790 confirmation Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000006180 TBST buffer Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 108010044426 integrins Proteins 0.000 description 11
- 102000006495 integrins Human genes 0.000 description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 102100030708 GTPase KRas Human genes 0.000 description 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 6
- 206010069755 K-ras gene mutation Diseases 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 229960002964 adalimumab Drugs 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 229960000397 bevacizumab Drugs 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 239000003929 acidic solution Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- -1 glycoside saponin Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 239000006152 selective media Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000005853 Clathrin Human genes 0.000 description 4
- 108010019874 Clathrin Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 210000004323 caveolae Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 229940022353 herceptin Drugs 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002082 metal nanoparticle Substances 0.000 description 4
- 229910052755 nonmetal Inorganic materials 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 3
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 3
- 101150073096 NRAS gene Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930193282 clathrin Natural products 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 239000011258 core-shell material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 229940048921 humira Drugs 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004020 intracellular membrane Anatomy 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102100035645 Biogenesis of lysosome-related organelles complex 1 subunit 1 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
- 101100326171 Homo sapiens BLOC1S1 gene Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- 229950001750 lonafarnib Drugs 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000034701 macropinocytosis Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000013426 primary mast cell activation syndrome Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001025319 Etheostoma collis Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 description 1
- 101710155665 Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001323321 Pluto Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000004651 endocytosis pathway Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- UGDGKPDPIXAUJL-UHFFFAOYSA-N ethyl n-[4-[benzyl(2-phenylethyl)amino]-2-(4-ethylphenyl)-1h-imidazo[4,5-c]pyridin-6-yl]carbamate Chemical compound N=1C(NC(=O)OCC)=CC=2NC(C=3C=CC(CC)=CC=3)=NC=2C=1N(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UGDGKPDPIXAUJL-UHFFFAOYSA-N 0.000 description 1
- RKWPMPQERYDCTB-UHFFFAOYSA-N ethyl n-[4-[benzyl(2-phenylethyl)amino]-2-(4-nitrophenyl)-1h-imidazo[4,5-c]pyridin-6-yl]carbamate Chemical compound N=1C(NC(=O)OCC)=CC=2NC(C=3C=CC(=CC=3)[N+]([O-])=O)=NC=2C=1N(CC=1C=CC=CC=1)CCC1=CC=CC=C1 RKWPMPQERYDCTB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004573 interface analysis Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000006333 protein structural change Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200006520 rs121913240 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Description
本発明の前記方法、完全型免疫グロブリン(immunoglobulin)形態の抗体が細胞質に浸透して細胞質内活性化されたRASと結合することを誘導する重鎖可変領域(VH)によって細胞内活性化されたRASを抑制させる。
配列番号8、11、14、17、20、23および26からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;
配列番号9、12、15、18、21、24および27からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;及び
配列番号10、13、16、19、22、25および28からなる群から選択されたアミノ酸配列からなるCDR3またはこれと相同性が90%以上である配列を含んでもよい。
配列番号32、35および38からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;及び
配列番号34,27および40からなる群から選択されたアミノ酸配列からなるCDR3またはこれと相同性が90%以上である配列を含んでもよい。
配列番号8、11、14、17、20、23および26からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;
配列番号9、12、15、18、21、24および27からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;及び
配列番号10、13、16、19、22、25および28からなる群から選択されたアミノ酸配列からなるCDR3またはこれと相同性が90%以上である配列を含んでもよい。
配列番号32、35および38からなる群から選択されたアミノ酸配列からなるCDR1またはこれと相同性が90%以上である配列;及び
配列番号34,27および40からなる群から選択されたアミノ酸配列からなるCDR3またはこれと相同性が90%以上である配列を含んでもよい。
また、本発明の一様態は、癌または腫瘍を治療する方法であって、前記方法は、個体に薬学的に有効な量の細胞質内活性化されたRASに特異的に結合する抗体を投与する工程を含むものである、方法を提供する。
また、本発明の一様態は、細胞質内RASに特異的に結合する重鎖可変領域のスクリーニング方法を提供する。
(2)GTPが結合されたRASと前記ライブラリーを結合させる工程;及び
(3)前記GTPが結合されたRASと前記ライブラリーとの結合の親和度を測定する工程を含む。
本明細書で使用された用語「診断」とは、病態生理の存在または特徴を確認することを意味する。本発明での診断は、癌の発病の有無および経過を確認するものである。
(1)活性化された(GTPが結合された)RASと特異的結合するヒト重鎖可変領域(VH)と重鎖不変領域(CH1−hinge−CH2−CH3)が含まれた核酸(nucleic acides)をクローニングした重鎖発現ベクターを製造する工程;
(2)前記製造された重鎖発現ベクターと細胞質浸透能を有する軽鎖可変領域を含む軽鎖発現ベクターをタンパク質発現用動物細胞に同時形質転換して生きている細胞の内部に浸透および細胞質分布して活性化された(GTPが結合された)RASを特異的認知する完全型免疫グロブリン形態の抗体を発現する工程;および
(3)前記発現された活性化された(GTPが結合された)RASを特異的認知する細胞質浸透能を有する完全型免疫グロブリン形態の抗体を精製、回収する工程。
また、本発明で提供する前記抗体の軽鎖可変領域またはこれを含む抗体は、特別な外部タンパク質伝達システムなしに生きている細胞の内部にエンドサイトーシス(endocytosis)およびエンドソーム脱出(endosome escape)過程を介して浸透して細胞質に分布することができる。特に、本発明で提供する抗体の軽鎖可変領域は、様々なヒト重鎖可変領域(VH)との相互作用結合が容易でありかつ細胞質浸透を介して細胞質に残留可能な特性を有して、前記軽鎖可変領域を含む完全IgG形態の単一クローン抗体は、細胞の内部浸透及び細胞質に分布して、細胞に非特異的細胞毒性を示さない。
図1は、細胞質浸透能だけ保有しているIgGフォーマットcytotransmabの重鎖可変領域(VH)をGTPが結合されたKRasに特異的結合する重鎖可変領域(VH)で置き換えた細胞浸透及び細胞内分布するGTPが結合されたRasに特異的に結合する単一クローン抗体(抗−Ras・GTP iMab:internalizing & interfering monoclonal antibody)を利用して、Ras突然変異細胞に対する特異的な細胞毒性を誘導する戦略に対する模式図である。
図2は、細胞質浸透能だけ保有している完全IgGフォーマットCytotransmabの重鎖可変領域(VH)をGTPが結合されたKRasに特異的結合する重鎖可変領域(VH)で置換を介して抗−Ras・GTP iMab構築を説明した模式図である。
前記の項−Ras・GTP iMabに導入するためのGTPが結合されたKRas特異的に結合する安定したヒト化重鎖可変領域単一ドメイン(VH)抗体切片を選別するために以前の研究を介して構築された酵母発現VHライブラリーを使用した(Baek and Kim,2014)。
ライブラリー選別および親和度分析のためのGTPが結合されたKRas G12D抗原を準備するために、大腸菌で発現精製した過程は、すでに発表した論文で詳しく記述されている(Tanaka T et al.,2007)。
図3は、GTPが結合されたKRas G12Dタンパク質に対してだけ特異的に高親和度を有するヒト化抗体重鎖可変領域単一ドメインを得るためのライブラリー選別戦略を示した模式図である。
図5は、cytotransmabと命名した細胞浸透を介して、細胞質に位置する完全IgG形態の単一クローン抗体の概念を示した模式図であり、これを具現するために、ヒト化抗体軽鎖可変領域の細胞質浸透能を理解するために、既存マウス由来軽鎖可変領域単一ドメインm3D8 VLの細胞質浸透性と軽鎖可変領域断片に属するCDRの相関に対する研究を参照した(Lee et al.,2013)。
前記実施例4でデザインされたhT2VL、hT3VLの実際の細胞質浸透能を比較するために、ヒト化軽鎖可変領域(VL)単一ドメインを精製した。
図6Aは、軽鎖可変領域単一ドメインの細胞質浸透能を共焦点顕微鏡(confocal microscopy)で観察した結果である。
図7Aは、hT3 VLの様々なヒト抗体重鎖可変領域に対して適用可能の有無を確認するために既存のヒト抗体Adalimumab(Humira)とヒト化抗体Bevacizumab(Avastin)の軽鎖可変領域(VL)とアミノ酸配列を分析した結果である。
図7Bは、追加的にヒト抗体重鎖可変領域と最適化された結合を介して安定的cytotransmab構築のための可変領域間のインターフェース残基を分析した結果である。
具体的には、既存文献を介してヒト抗体可変領域間のインターフェース残基位置および反対側可変領域に位置した特定インターフェース残基と結合頻度、インターフェース残基のヒト抗体での使用頻度を資料を根拠に、hT3 VLとFDAに承認された治療用抗体Bevacizumab(Avastin)、Adalimumab(Humira)の重鎖、軽鎖可変領域間のインターフェースを分析した(Vargas−Madrazo and Paz−Garcia,2003)。分析結果、hT3 VLのマウス由来CDRで可変領域間の結合に関与するCDR3に含まれた89番、91番残基がヒト抗体使用頻度が高い地域であり、重鎖可変領域(VH)のCDR3の構造に影響を与え得ることを確認した。この二つの残基をヒト抗体で使用頻度が高いアミノ酸で突然変異してヒト抗体重鎖可変領域と最適化された結合ができるhT4 VLを開発した。
図8は、cytotransmab構築のために細胞浸透能がない軽鎖可変領域を細胞質浸透能を有するヒト化軽鎖可変領域を置き換える方法に対する全般的な模式図である。
図9Aは、細胞質浸透能を有する軽鎖可変領域hT4 VLで軽鎖可変領域が置き換えられたcytotransmabの細胞質浸透能を検証するために、様々な細胞株で1〜2個の細胞に焦点を合わせて共焦点顕微鏡で観察した結果である。
細胞質浸透能を有するヒト化軽鎖可変領域が導入されたcytotransmabの場合、すべての細胞で細胞質浸透を介して細胞質に分布することを確認した。
前記実施例9で細胞質浸透能を有しているcytotransmabがIn vitro上で、細胞毒性を有するかを確認するために、HeLa、PANC−1細胞株にTMab4、HuT4、Adalimumab、AvaT4、Bevacizumabを処理して細胞成長阻害程度をMTT assay(sigma)を介して確認した。
細胞浸透及び細胞質に位置する特性を有するcytotransmabの重鎖可変領域(VH)を前記実施例3で選別されたRT4 VHで置き換えて細胞浸透を介して細胞内GTPが結合されたRasを特異的に標的が可能な抗−Ras・GTP iMab構築及び動物細胞で発現した。
図11は、抗−Ras・GTP iMab RT4の精製後、還元性または非還元性条件で12%SDS−PAGEを介して分析したものである。
図14は、抗−Ras・GTP iMab RT4の細胞質浸透能を確認するために、共焦点顕微鏡で観察した結果である。KRas突然変異を有する細胞株(PANC−1、HCT116)とKRas野生型を種々の細胞株を(HT29、HeLa)で抗−Ras・GTP iMab RT4の細胞浸透能を観察した。
(1)抗−Ras・GTP iMabの付着性細胞成長抑制評価
図15は、NIH3T3、NIH3T3 KRas G12V、NIH3T3 HRas G12V細胞株で抗−Ras・GTP iMab RT4を処理して細胞成長阻害程度をin vitroで評価した結果である。
図16は、NIH3T3 HRas G12V細胞株で非付着性細胞成長阻害を評価した結果である。
前記結果から、抗−Ras・GTP iMab RT4は、細胞質にあるRas突然変異に特異的に結合して付着性および非付着性細胞成長を抑制することを確認した。
図17は、抗−Ras・GTP iMab RT4と細胞内活性化したHRas G12V突然変異との重なりの可否を共焦点顕微鏡で確認した結果である。図18は、抗−Ras・GTP iMabと細胞内GTPが結合されたKRas G12V突然変異との重なりの可否を共焦点顕微鏡で確認した結果である。
前記実験結果により、細胞内のGTPが結合されたRasと抗−Ras・GTP iMab RT4が特異的に結合することを確認した。
In vivo実験のためには、腫瘍組織特異性を与える必要がある。既存cytotransmabの場合、細胞表面にHSPGと結合して、その他のいかなる腫瘍組織特異性を有しないため、in vivo実験で腫瘍に対する特異的生長阻害ができない可能性が高い。これを改善するために、新生血管細胞および様々な腫瘍で過発現されるインテグリン(Integrin αvβ3)に特異性を有するRGD4Cペプチド(CDCRGDCFC、配列番号41)を軽鎖N−末端にGGGGS1個のリンカーを使用して遺伝工学的に融合した。RGD4Cペプチドの場合、既存RGDペプチドよりも高い親和度を有していて、遺伝工学的融合が可能で、N−末端に融合時にもRGDペプチドの特定構造を維持できる特徴がある(Koivunen E et al.,1995)。
In vitro上で、RGD−TMab4とRGD−RT4自体が細胞毒性を有するのか確認するために、KRas G13D突然変異を有しているヒト大腸癌細胞株であるHCT116とKRas G12D突然変異を有しているヒトすい臓癌細胞株であるPANC−1にRGD−TMab4とRGD−RT4をそれぞれ処理して細胞成長阻害程度を評価した。
図20Aは、HCT116細胞株を異種移植したマウスでRGDが融合した抗−Ras・GTP iMab RT4の腫瘍成長抑制効果を確認した実験結果である。図20Bは、RGDが融合した抗−Ras・GTP iMab RT4の非特異的副作用を確認するためにマウスの体重を測定したグラフである。
抗−Ras・GTP iMab RT4の場合、Ras特異的生物学的活性を示すが、SPR分析を介して得た親和度が約110nM水準でIgGフォーマット抗体であるにもかかわらず抗原に対する親和度が非常に低い。これを克服して低い濃度でも生物学的活性を向上させるために親和度改良が必要である。
具体的に、デザインされたライブラリーコードするDNAは、PCR法を利用して増幅後、エタノール沈殿法を使用して濃縮した。相同性接合(Homologous recombination)のためのpYDS−H重鎖単一鎖酵母表面発現ベクターは、NheIとApaI制限酵素を処理して、及びアガロースゲル抽出法を利用して精製及びエタノール沈殿法を利用して濃縮した。それぞれライブラリーコードDNA12μgに対して制限酵素処理された5μgベクターを酵母表面発現用接合Aタイプ(Mating type A)酵母JAR200に電気穿孔法で形質転換して(Baek D.S and Kim Y.S,2014;Lorenzo B et al.,2010)、階段式希薄(serial dilution)を介して選択培地SD−CAA+URA(20g/L Glucose、6.7g/L Yeast nitrogen base without amino acids、5.4g/L Na2HPO4、8.6g/L NaH2PO4、5g/L casamino acids、0.2mg/L Uracil)で育ったコロニーの数を測定してライブラリーの大きさを確認した。
下記の表4はRT4を含みRT4を鋳型にした親和度改良ライブラリーから選別された個別クローンのヒト抗体の重鎖可変領域(VH)配列であり、下記の表5は前記選別されたRas・GTP特異的重鎖可変領域(VH)のCDR1、2及び3の配列である。
前記実施例11のようにライブラリー選別を介して、Ras・GTPに向上した親和度を有する重鎖可変領域と重鎖不変領域(CH1−hinge−CH2−CH3)が含まれた重鎖を動物発現ベクターにクローニングして、細胞質浸透ヒト化軽鎖発現ベクターとHEK293Fタンパク質発現細胞に同時に一時的トランスフェクション(transient transfection)して、抗−Ras・GTP iMabを発現して、前記実施例11と同様に精製した。
図24は、親和度が改良された抗−RAS・GTP iMabは精製後、還元性または非還元性条件で12%SDS−PAGEを介して分析したものである。
図25は、抗−Ras・GTP iMabの重鎖可変領域を親和度が向上されたRas・GTP特異的な重鎖可変領域に取り替えた後、細胞浸透能を有するか確認するために共焦点顕微鏡で観察した結果である。
図26Aは、KRas G12DのGTPが結合された形態とGDPが結合された形態での親和度が改良された抗−Ras・GTP iMabの親和度を測定するためのELISA実行結果である。
図26Bは、前記ELISA基盤結合能分析を介して選定されたRT11を様々なRas突然変異に対してGTPが結合されたRas高特異的結合能をELISAを介して分析した。
図26Bにしめされたとおり、抗−Ras・GTP iMab RT11は様々な突然変異Rasに対してGTPが結合された形態だけで結合することを確認した。
抗−Ras・GTP iMab RT11のGTPが結合されたKRas G12Dに対する定量的結合能を分析するため、SPR(Surface plasmon resonance)を行った。Biacore2000機器(GE healthcare)を利用した。
図27Aは、SPR(BIACORE2000)(GE healthcare)を利用してKRas G12DにGTPが結合形態に対する抗−Ras・GTP iMab RT11の親和度分析結果を示す。
図27Bは、最も高い濃度(1000nM)のGTPまたはGDPが結合されたKRas G12Dに対するRT11の結合能をSPRを利用して分析したsensorgramである。
前記結果を介してRT11が高い親和度(12.9nM)でGTPが結合されたKRas G12Dに高特異的に結合することを確認した。
図28は、抗−Ras・GTP iMab RT11が細胞内KRasと結合する効果タンパク質(effector molecule)であるRafとの結合を阻害できるのか競合的ELISAを介して確認した結果である。
図28に示されたとおり抗−Ras・GTP iMab RT11は、効果タンパク質cRafとの結合阻害能(IC50=35nM)を示すことを確認した。
図29は、親和度が向上された抗−Ras・GTP iMabの様々な腫瘍細胞に細胞浸透能を有するのか確認するために共焦点顕微鏡で観察した結果である。
具体的には、上述の多様なRas突然変異及びRas野生型細胞株を24ウェルプレートに各ウェル当たり5x104個で10%FBSが含まれた培地0.5mlに入れて12時間5%CO2、37℃条件で培養した。細胞が安定化されると、各ウェルに新しい培地0.5mlにTMab4、RT11をそれぞれ2μMで希釈して12時間37℃、5%CO2条件で培養した。以後の過程は、前記実施例14のRT4染色過程と同様に行われた。親和度向上された抗−Ras・GTP iMabであるRT11は、多様な腫瘍細胞内蛍光が観察できることから、TMab4と同様に多様な腫瘍細胞株に細胞浸透能を有することを確認した。
図30は、親和度が向上した抗−Ras・GTP iMabの細胞質残留能を細胞膜非透過自己消光蛍光物質であるcalcein(sigma)を利用して共焦点顕微鏡で観察した結果である。
図31は、様々なRas野生型及びRas突然変異細胞株で抗−Ras・GTP iMab RT11を処理して細胞成長阻害程度をin vitroで評価した結果であり、図32は、それぞれの細胞を偏光顕微鏡を介して細胞密度を確認した写真である。
(1)抗−Ras・GTP iMab RT11の細胞内のRas・GTPと特異的結合確認
図33は、RT11と細胞内活性化されたKRas G12V突然変異との重なりの可否を共焦点顕微鏡で確認した結果である。
図34は、RT11と細胞内活性化されたRASとの結合の可否を免疫沈降法で確認した結果である。
図34に示されたとおり、RT11でだけKRasが観察された反面、TMab4とPBSでは観察されなかった。
前記実験結果から細胞内の活性化されたRASとRT11が特異的に結合することを確認した。
図35A及び図35Bは、RT11のRas・GTPと効果タンパク質との間の結合抑制の可否を免疫沈降法で確認した結果である。
前記実験結果からRT11が細胞内のRas・GTPと特異的に結合して効果タンパク質であるB−Raf、C−Rafとの結合を抑制することを確認した。
前記実施例15のように抗−Ras・GTP iMab RT11は細胞表面のHSPGと結合を介して細胞質浸透が行われるため、in vivo実験のために組織特異性を付与する必要があって、これのために新生血管細胞及び多様な腫瘍から過発現されるインテグリン(Integrin αvβ3)に特異性を有するRGD10ペプチド(DGARYCRGDCFDG、配列番号42)を軽鎖N−末端にGGGGSGGGGS計10個の残基からなるリンカーを使用して遺伝工学的に融合した。RGD10ペプチドの場合、既存RT4と融合したRGD4Cペプチドと比較してインテグリンに対する親和度が類似して、ペプチド内のジスルフィド結合が1個であり、抗体N−末端に融合がRGD4Cより容易であると予想され抗−Ras・GTP iMab RT11に遺伝工学的に融合した。
図36に示されたとおり、RT11とRGD10ペプチドが融合されたRGD10−RT11がGTPが結合されたRas突然変異に対して同様の結合力を示すことを確認した。
図37及び図38は、Colo320DM、HCT116、PANC−1、SW480、DLD−1細胞株でRGD10−TMab4とRGD10−RT11を処理して細胞成長阻害程度をin vitroで評価した結果である。
図39は、RGD10−TMab4とRGD10−RT11が細胞表面のintegrin ανβ3に特異的に結合するのか確認した結果である。
図39に示されたとおり、TMab4とは異なってRGD10−TMAb4、RGD10−RT11はK562 integrin ανβ3細胞に特異的に結合することを確認した。これにより、RGD10ペプチドがintegrin ανβ3に特異的に結合することを確認した。
図40は、RGD10−RT11と細胞内活性化されたKRas G12V突然変異との重なりの可否を共焦点顕微鏡で確認した結果である。
Claims (8)
- 細胞を透過しそして細胞質に位置する能力及び細胞質内で特異的に活性化RASに結合する能力を有する完全型免疫グロブリンタイプの抗体であって、
前記抗体は、細胞質内で特異的に活性化RASに結合する重鎖可変領域(VH)、及び生細胞を透過し、細胞質に位置する能力を有する軽鎖可変領域を(VL)を含み、
前記重鎖可変領域(VH)は、
配列番号8のアミノ酸配列を含むCDR1、配列番号9のアミノ酸配列を含むCDR2、及び配列番号10のアミノ酸配列を含むCDR3;
配列番号11のアミノ酸配列を含むCDR1、配列番号12のアミノ酸配列を含むCDR2、及び配列番号13のアミノ酸配列を含むCDR3;
配列番号14のアミノ酸配列を含むCDR1、配列番号15のアミノ酸配列を含むCDR2、及び配列番号16のアミノ酸配列を含むCDR3;
配列番号17のアミノ酸配列を含むCDR1、配列番号18のアミノ酸配列を含むCDR2、及び配列番号19のアミノ酸配列を含むCDR3;
配列番号20のアミノ酸配列を含むCDR1、配列番号21のアミノ酸配列を含むCDR2、及び配列番号22のアミノ酸配列を含むCDR3;
配列番号23のアミノ酸配列を含むCDR1、配列番号24のアミノ酸配列を含むCDR2、及び配列番号25のアミノ酸配列を含むCDR3;又は
配列番号26のアミノ酸配列を含むCDR1、配列番号27のアミノ酸配列を含むCDR2、及び配列番号28のアミノ酸配列を含むCDR3;を含み、
そして前記軽鎖可変領域(VL)は、
配列番号29、30、及び31からなる群から選択されたアミノ酸配列を含む、
前記抗体。 - 前記抗体は、生細胞に能動的に浸透して細胞質で活性化RASに特異的に結合する請求項1に記載の抗体。
- 前記軽鎖可変領域(VL)が、エンドサイトーシスを受け、そしてその後にエンドソームを脱出することによって、生細胞を透過しそして細胞質に位置する、請求項1に記載の抗体。
- 前記重鎖可変領域は、配列番号1〜7からなる群から選択されたアミノ酸配列を含む請求項1に記載の抗体。
- 前記抗体が、ペプチド、タンパク質、小分子薬物、ナノ粒子及びリポソームからなる群から選択された生体活性分子に融合した、請求項1〜4のいずれか一項に記載の抗体。
- 前記ペプチドが、配列番号41で表されるアミノ酸配列を含むRGD4C、又は配列番号42で表されるアミノ酸配列を含むRGD10である、請求項5に記載の抗体。
- 癌又は腫瘍の治療又は予防方法に使用するための、請求項1〜6のいずれか一項に記載の抗体。
- 請求項1〜4のいずれか一項に記載の抗体をコードするポリヌクレオチド。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0092687 | 2014-07-22 | ||
KR20140092687 | 2014-07-22 | ||
KR1020150103214A KR101602876B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
KR10-2015-0103214 | 2015-07-21 | ||
PCT/KR2015/007627 WO2016013871A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017529870A JP2017529870A (ja) | 2017-10-12 |
JP2017529870A5 JP2017529870A5 (ja) | 2018-08-30 |
JP6798988B2 true JP6798988B2 (ja) | 2020-12-09 |
Family
ID=55354089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017525496A Expired - Fee Related JP6798988B2 (ja) | 2014-07-22 | 2015-07-22 | 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたrasを抑制する方法及びその利用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10851177B2 (ja) |
EP (1) | EP3173099B1 (ja) |
JP (1) | JP6798988B2 (ja) |
KR (2) | KR101602876B1 (ja) |
CN (1) | CN106999575A (ja) |
AU (1) | AU2015292956B2 (ja) |
BR (1) | BR112017001306A2 (ja) |
CA (1) | CA2955265A1 (ja) |
IL (1) | IL250137B (ja) |
MX (1) | MX2017001012A (ja) |
RU (1) | RU2017103679A (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
US11155641B2 (en) * | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
EP3712180A4 (en) * | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
EP3827024A4 (en) * | 2018-07-23 | 2022-06-08 | Chugai Seiyaku Kabushiki Kaisha | TARGET CELL-SPECIFIC CYTOSOL-PENETRATING ANTIGEN-BINDING MOLECULES |
KR20200088780A (ko) * | 2019-01-15 | 2020-07-23 | 오름테라퓨틱 주식회사 | 세포질 침투성이 증진된 항체 |
WO2020221849A1 (en) * | 2019-05-01 | 2020-11-05 | Universidade De Santiago De Compostela | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
WO2021222333A1 (en) * | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
CA3214155A1 (en) * | 2021-04-02 | 2022-10-06 | Ryan B. CORCORAN | Methods for inhibiting ras |
CN117916258A (zh) | 2021-07-20 | 2024-04-19 | 亚洲大学校产学协力团 | 穿透进细胞以降解和去除靶蛋白的细胞穿透降解抗体及其用途 |
WO2023044432A2 (en) * | 2021-09-17 | 2023-03-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeting mutant kras with a mutation specific iga |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
CN1241574A (zh) | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
AU2003219277A1 (en) * | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
CA2506128A1 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
CA2647102A1 (en) * | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
KR100849941B1 (ko) | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
EP2279002B1 (en) | 2008-04-30 | 2013-08-14 | Ajou University Industry-Academic Cooperation Foundation | Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
KR101075123B1 (ko) * | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
EP2346899A4 (en) * | 2008-11-11 | 2013-01-02 | Ajou Univ Ind Acad Coop Found | CELL PENETRATING SEQUENCE-SPECIFIC AND NUCLEIC ACID HYDROLYZING ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH |
CN101402675B (zh) * | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
GB201103631D0 (en) * | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
WO2012135831A1 (en) | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
JP6246128B2 (ja) | 2012-09-14 | 2017-12-13 | 公益財団法人がん研究会 | EpCAMに結合するペプチド |
US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
WO2016013870A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
SG10201913158PA (en) | 2015-04-03 | 2020-02-27 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
US11155641B2 (en) | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
EP3712180A4 (en) | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103214A patent/KR101602876B1/ko active IP Right Grant
- 2015-07-22 CN CN201580045140.3A patent/CN106999575A/zh active Pending
- 2015-07-22 US US15/327,539 patent/US10851177B2/en active Active
- 2015-07-22 AU AU2015292956A patent/AU2015292956B2/en not_active Ceased
- 2015-07-22 BR BR112017001306-1A patent/BR112017001306A2/pt not_active Application Discontinuation
- 2015-07-22 RU RU2017103679A patent/RU2017103679A/ru not_active Application Discontinuation
- 2015-07-22 CA CA2955265A patent/CA2955265A1/en not_active Abandoned
- 2015-07-22 EP EP15825508.3A patent/EP3173099B1/en active Active
- 2015-07-22 JP JP2017525496A patent/JP6798988B2/ja not_active Expired - Fee Related
- 2015-07-22 MX MX2017001012A patent/MX2017001012A/es unknown
-
2016
- 2016-02-12 KR KR1020160016637A patent/KR101732553B1/ko active IP Right Grant
-
2017
- 2017-01-16 IL IL250137A patent/IL250137B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US10851177B2 (en) | 2020-12-01 |
CN106999575A (zh) | 2017-08-01 |
AU2015292956A1 (en) | 2017-02-09 |
RU2017103679A (ru) | 2018-08-06 |
KR101732553B1 (ko) | 2017-05-08 |
BR112017001306A2 (pt) | 2018-01-30 |
US20170158777A1 (en) | 2017-06-08 |
EP3173099B1 (en) | 2020-03-04 |
AU2015292956B2 (en) | 2020-04-02 |
JP2017529870A (ja) | 2017-10-12 |
EP3173099A1 (en) | 2017-05-31 |
IL250137A0 (en) | 2017-03-30 |
KR20160011599A (ko) | 2016-02-01 |
MX2017001012A (es) | 2018-06-19 |
KR101602876B1 (ko) | 2016-03-11 |
IL250137B (en) | 2020-05-31 |
KR20160033670A (ko) | 2016-03-28 |
EP3173099A4 (en) | 2018-03-14 |
CA2955265A1 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6798988B2 (ja) | 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたrasを抑制する方法及びその利用 | |
JP6595592B2 (ja) | 完全型免疫グロブリン形態の抗体を細胞膜を透過して細胞質に位置させる方法およびその利用 | |
US20200362010A1 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
EP2835380B1 (en) | Method of blocking vascular leakage using an anti-Ang2 antibody | |
KR102163305B1 (ko) | 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도 | |
JP6391676B2 (ja) | ニューロピリンに特異的な腫瘍浸透性ペプチド及びこのペプチドが融合された融合タンパク質 | |
US11155641B2 (en) | Cytosol-penetrating antibody and use thereof | |
KR102091195B1 (ko) | 세포질 침투 항체 및 이의 용도 | |
KR20180129514A (ko) | 세포질 침투 항체 및 이의 용도 | |
KR20200088780A (ko) | 세포질 침투성이 증진된 항체 | |
EP3466970A1 (en) | Cytosol-penetrating antibody and use thereof | |
NZ749020B2 (en) | Cytosol-penetrating antibody and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180720 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6798988 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |